Analysis of acute antibody-mediated rejection following liver transplantation for hepatocellular carcinoma post-immune therapy: a case series of three reports
10.3760/cma.j.cn421203-20240702-00158
- VernacularTitle:免疫治疗后肝细胞癌肝移植受者发生急性抗体介导排斥反应3例
- Author:
Qianyong ZHAO
1
;
Bo ZHANG
1
;
Bo YANG
1
;
Yuanyuan ZHAO
1
;
Lai WEI
1
;
Zhishui CHEN
1
;
Dong CHEN
1
Author Information
1. 华中科技大学同济医学院附属同济医院器官移植研究所 器官移植教育部重点实验室 国家卫生健康委员会器官移植重点实验室 中国医学科学院器官移植重点实验室，武汉 430030
- Publication Type:Journal Article
- Keywords:
Liver Transplantation;
Hepatocellular carcinoma;
Immune checkpoint inhibitor;
Graft rejection;
Donor specific antibody
- From:
Chinese Journal of Organ Transplantation
2025;46(8):606-609
- CountryChina
- Language:Chinese
-
Abstract:
This article retrospectively analyzed the clinical data of three recipients who developed acute antibody mediated rejection (AMR) after receiving different courses of immunotherapy prior to liver transplantation for hepatocellular carcinoma. It focused on their diagnostic and therapeutic processes, including the immunosuppressive induction regimen [rabbit anti-human thymocyte globulin (rATG) + methylprednisolone] , postoperative liver function changes, diagnostic methods for acute AMR (such as allograft liver biopsy, panel reactive antibody testing, and donor-specific antibody testing) , and the combination treatment strategies used (rATG, rituximab, intravenous immunoglobulin, and plasma exchange). The aim of this article is to summarize the clinical characteristics, diagnosis, and treatment experiences of acute AMR occurring after liver transplantation in patients with liver cancer who had received immunotherapy, explore the potential risks involved, and provide a reference for clinicians in managing such cases.
